Analyst Ratings (USA)
American analyst updates for today show selective optimism in AI infrastructure, cybersecurity and healthcare, alongside caution across transportation, housing-related businesses and insurance. Marvell and Zscaler received numerous target increases, while healthcare coverage initiations highlighted opportunities in medical technology. However, target reductions across airlines and freight operators, plus downgrades in building products, suggest a less uniform outlook for economically sensitive sectors.
Analyst Updates (463)
10x Genomics (TXG) — Barclays maintained its Overweight rating and raised its price target to US$110.00 from US$52.00.
Abbott Laboratories (ABT) — Barclays initiated coverage with an Overweight rating and a price target of US$120.00.
AbbVie (ABBV) — Morgan Stanley maintained its Overweight rating and raised its price target to US$310.00 from US$296.00.
Abercrombie & Fitch (ANF) — BTIG Research reiterated its Buy rating and a price target of US$175.00.
Adeia (ADEA) — BWS Financial reiterated its Buy rating and a price target of US$50.00.
Adient (ADNT) — UBS maintained its Buy rating and lowered its price target to US$23.00 from US$29.00.
Aflac (AFL) — Barclays reiterated its Underweight rating and raised its price target to US$101.00 from US$99.00.
Aflac (AFL) — Mizuho maintained its Underperform rating and lowered its price target to US$107.00 from US$116.00.
Afya (AFYA) — JPMorgan upgraded its rating to Overweight from Neutral and lowered its price target to US$19.00 from US$21.00.
Agilent Technologies (A) — Barclays maintained its Overweight rating and raised its price target to US$195.00 from US$175.00.
Agios Pharmaceuticals (AGIO) — Truist Securities maintained its Buy rating and lowered its price target to US$37.00 from US$39.00.
Air Products and Chemicals (APD) — Citigroup maintained its Neutral rating and lowered its price target to US$312.00 from US$330.00.
Airbnb (ABNB) — Wells Fargo maintained its Overweight rating and lowered its price target to US$185.00 from US$186.00.
Alaska Air Group (ALK) — Susquehanna maintained its Positive rating and lowered its price target to US$50.00 from US$55.00.
Albemarle (ALB) — Argus maintained its Buy rating and lowered its price target to US$135.00 from US$230.00.
Albertsons Companies (ACI) — RBC Capital Markets reiterated its Outperform rating and a price target of US$13.00.
Alcoa (AA) — JPMorgan maintained its Neutral rating and lowered its price target to US$50.00 from US$52.00.
Alcoa (AA) — Morgan Stanley maintained its Equal Weight rating and lowered its price target to US$50.00 from US$53.00.
Alcon (ALC) — Barclays initiated coverage with an Equal Weight rating and a price target of US$70.00.
Allegiant Travel (ALGT) — Raymond James reiterated its Strong Buy rating and a price target of US$110.00.
Allegiant Travel (ALGT) — Susquehanna maintained its Neutral rating and lowered its price target to US$85.00 from US$110.00.
Allstate (ALL) — Barclays maintained its Underweight rating and lowered its price target to US$221.00 from US$226.00.
Allstate (ALL) — HSBC upgraded its rating to Buy from Hold with a price target of US$266.00.
Allstate (ALL) — Mizuho maintained its Outperform rating and lowered its price target to US$295.00 from US$300.00.
Ambev (ABEV) — BofA Securities downgraded its rating to Underperform from Neutral with a price target of US$3.30.
Ambiq Micro (AMBQ) — Jefferies initiated coverage with a Buy rating and a price target of US$90.00.
American Airlines Group (AAL) — Susquehanna maintained its Positive rating and lowered its price target to US$15.00 from US$20.00.
American Axle & Manufacturing (DCH) — UBS maintained its Buy rating and lowered its price target to US$8.00 from US$9.00.
American International Group (AIG) — Mizuho maintained its Neutral rating and lowered its price target to US$83.00 from US$85.00.
AMETEK (AME) — DA Davidson set its price target at US$285.00.
Amgen (AMGN) — Morgan Stanley maintained its Equal Weight rating and lowered its price target to US$359.00 from US$362.00.
Amgen (AMGN) — Truist Securities maintained its Hold rating and raised its price target to US$380.00 from US$362.00.
Amphenol (APH) — UBS reiterated its Buy rating and raised its price target to US$105.00 from US$99.00.
Anteris Technologies Global Corp. (AVR) — Barclays initiated coverage with an Equal Weight rating and a price target of US$10.00.
AON (AON) — Barclays maintained its Equal Weight rating and lowered its price target to US$317.00 from US$382.00.
AON (AON) — Cantor Fitzgerald maintained its Overweight rating and lowered its price target to US$400.00 from US$433.00.
AON (AON) — Mizuho maintained its Outperform rating and lowered its price target to US$324.00 from US$366.00.
AppFolio (APPF) — UBS downgraded its rating to Neutral from Buy and raised its price target to US$220.00 from US$200.00.
AptarGroup (ATR) — Deutsche Bank initiated coverage with a Buy rating and a price target of US$150.00.
Aptiv (APTV) — UBS maintained its Buy rating and lowered its price target to US$57.00 from US$62.00.
ArcBest (ARCB) — Citigroup maintained its Buy rating and lowered its price target to US$170.00 from US$173.00. An additional same-day entry listed a Cautious outlook without a target.
ArcBest (ARCB) — Truist Securities maintained its Buy rating and lowered its price target to US$160.00 from US$165.00.
Arch Capital Group (ACGL) — Cantor Fitzgerald maintained its Neutral rating and lowered its price target to US$105.00 from US$110.00.
Arista Networks (ANET) — Evercore ISI reiterated its Outperform rating.
ArriVent BioPharma (AVBP) — BTIG Research maintained its Buy rating and lowered its price target to US$29.00 from US$42.00.
ArriVent BioPharma (AVBP) — Citigroup maintained its Buy rating and lowered its price target to US$20.00 from US$40.00.
ArriVent BioPharma (AVBP) — Guggenheim maintained its Buy rating and lowered its price target to US$18.00 from US$45.00.
ArriVent BioPharma (AVBP) — JonesTrading maintained its Buy rating and lowered its price target to US$22.00 from US$45.00.
Arthur J. Gallagher & Co. (AJG) — Cantor Fitzgerald maintained its Neutral rating and lowered its price target to US$280.00 from US$300.00.
Arthur J. Gallagher & Co. (AJG) — Mizuho maintained its Outperform rating and lowered its price target to US$271.00 from US$292.00.
Arthur J. Gallagher & Co. (AJG) — Oppenheimer initiated coverage with a Perform rating (Market Perform in the other feed).
Asbury Automotive Group (ABG) — UBS maintained its Neutral rating and lowered its price target to US$193.00 from US$250.00.
ASML (ASML) — RBC Capital Markets reiterated its Outperform rating and a price target of US$2,100.00.
AT&T (T) — KeyBanc Capital Markets reiterated its Overweight rating and a price target of US$36.00.
Atour Lifestyle (ATAT) — HSBC initiated coverage with a Buy rating and a price target of US$39.70.
AutoNation (AN) — UBS maintained its Buy rating and lowered its price target to US$213.00 from US$248.00.
Avantor (AVTR) — Barclays maintained its Underweight rating and raised its price target to US$15.00 from US$13.00.
Axis Capital (AXS) — Mizuho maintained its Outperform rating and lowered its price target to US$116.00 from US$118.00.
AxoGen (AXGN) — Barclays initiated coverage with an Overweight rating and a price target of US$55.00.
Bausch + Lomb (BLCO) — Barclays initiated coverage with an Overweight rating and a price target of US$24.00.
Baxter International (BAX) — Barclays initiated coverage with an Underweight rating and a price target of US$20.00.
Beasley Broadcast Group (BBGI) — Noble Financial reiterated its Outperform rating.
Becton, Dickinson and Company (BDX) — Barclays initiated coverage with an Underweight rating and a price target of US$165.00.
BeOne Medicines (ONC) — Truist Securities maintained its Buy rating and raised its price target to US$420.00 from US$418.00.
Beta Bionics (BBNX) — Barclays initiated coverage with an Overweight rating and a price target of US$30.00.
Better Home & Finance (BETR) — Cantor Fitzgerald changed its rating to Overweight from Hold.
Better Home & Finance (BETR) — Northland Securities set its price target at US$18.00.
Biomea Fusion (BMEA) — Brookline Capital Markets initiated coverage with a Buy rating.
BioNTech (BNTX) — Morgan Stanley maintained its Overweight rating and lowered its price target to US$114.00 from US$115.00.
Black Hills (BKH) — Freedom Broker upgraded its rating to Buy from Hold and raised its price target to US$78.00 from US$69.00.
BlackRock (BLK) — Barclays maintained its Overweight rating and lowered its price target to US$1,420.00 from US$1,450.00.
BlackRock (BLK) — UBS maintained its Buy rating and lowered its price target to US$1,277.00 from US$1,320.00.
Bloom Energy (BE) — Bernstein reiterated its Market Perform rating and a price target of US$282.00.
Bloom Energy (BE) — UBS maintained its Buy rating and raised its price target to US$350.00 from US$325.00.
Booking (BKNG) — Wells Fargo reiterated its Reduce rating and lowered its price target to US$190.00 from US$220.00.
Booz Allen Hamilton (BAH) — Citigroup maintained its Neutral rating and lowered its price target to US$77.00 from US$82.00.
Booz Allen Hamilton (BAH) — Jefferies maintained its Hold rating and lowered its price target to US$75.00 from US$80.00.
BorgWarner (BWA) — UBS maintained its Buy rating and lowered its price target to US$91.00 from US$95.00.
Boston Scientific (BSX) — Barclays initiated coverage with an Equal Weight rating and a price target of US$48.00.
Boyd Gaming (BYD) — Mizuho maintained its Outperform rating and lowered its price target to US$102.00 from US$104.00.
BridgeBio Pharma (BBIO) — Barclays maintained its Overweight rating and lowered its price target to US$156.00 from US$157.00.
BrightSpire Capital (BRSP) — Citigroup reiterated its Market Outperform rating.
BrightSpire Capital (BRSP) — Citizens JMP Securities maintained its Market Outperform rating and lowered its price target to US$6.00 from US$7.00.
BrightSpire Capital (BRSP) — Goldman Sachs upgraded its rating to Buy.
Bristol Myers Squibb (BMY) — Morgan Stanley reiterated its Underweight rating and raised its price target to US$41.00 from US$40.00.
Brixmor Property Group (BRX) — KeyBanc Capital Markets reiterated its Overweight rating and a price target of US$34.00.
Brown & Brown (BRO) — Barclays maintained its Equal Weight rating and lowered its price target to US$71.00 from US$76.00.
Brown & Brown (BRO) — Mizuho maintained its Outperform rating and lowered its price target to US$78.00 from US$83.00.
Brown & Brown (BRO) — Oppenheimer initiated coverage with an Outperform rating and a price target of US$73.00.
Bruker (BRKR) — Barclays maintained its Overweight rating and raised its price target to US$70.00 from US$58.00.
Builders FirstSource (BLDR) — RBC Capital Markets downgraded its rating to Sector Perform from Outperform with a price target of US$62.00.
C.H. Robinson Worldwide (CHRW) — Truist Securities maintained its Buy rating and lowered its price target to US$200.00 from US$215.00.
CACI International (CACI) — Citigroup maintained its Neutral rating and raised its price target to US$689.00 from US$648.00.
Cadence Design Systems (CDNS) — Deutsche Bank reiterated its Buy rating and a price target of US$420.00.
Canadian National Railway (CNI) — Citigroup maintained its Buy rating and lowered its price target to US$143.00 from US$151.00.
Canadian Pacific Kansas City (CP) — Citigroup maintained its Buy rating and lowered its price target to US$102.00 from US$109.00. An additional same-day entry listed a Cautious outlook without a target.
CarGurus (CARG) — UBS maintained its Neutral rating and lowered its price target to US$35.00 from US$40.00.
Caribou Biosciences (CRBU) — Brookline Capital Markets changed its rating to Hold from Buy.
Caribou Biosciences (CRBU) — Leerink Partners downgraded its rating to Market Perform from Outperform and lowered its price target to US$1.00 from US$4.00.
Caribou Biosciences (CRBU) — RBC Capital Markets downgraded its rating to Sector Perform from Outperform with a price target of US$1.00.
Carrier Global (CARR) — Bernstein maintained its Market Perform rating and lowered its price target to US$64.00 from US$78.00.
Cars.com (CARS) — UBS maintained its Neutral rating and lowered its price target to US$11.50 from US$13.00.
Cencora (COR) — Leerink Partners maintained its Outperform rating and raised its price target to US$388.00 from US$380.00.
Certara (CERT) — Barclays maintained its Equal Weight rating and raised its price target to US$9.00 from US$7.50.
Charles Schwab (SCHW) — Barclays maintained its Overweight rating and lowered its price target to US$118.00 from US$125.00.
Charles Schwab (SCHW) — UBS maintained its Buy rating and lowered its price target to US$113.00 from US$128.00.
Cheniere Energy (LNG) — Barclays maintained its Overweight rating and raised its price target to US$287.00 from US$279.00.
Chubb (CB) — Cantor Fitzgerald maintained its Neutral rating and raised its price target to US$333.00 from US$330.00.
Chubb (CB) — HSBC reiterated its Hold rating and a price target of US$359.00.
Chubb (CB) — Mizuho maintained its Neutral rating and lowered its price target to US$336.00 from US$347.00.
Citizens (CIZN) — Jefferies set its price target at US$14.00.
Citizens Financial Group (CFG) — Raymond James resumed coverage with a Strong Buy rating and a price target of US$77.00.
CLEAR Secure (YOU) — Needham reiterated its Buy rating and a price target of US$70.00.
CME Group (CME) — Barclays maintained its Equal Weight rating and raised its price target to US$281.00 from US$270.00.
Coinbase Global (COIN) — Barclays maintained its Underweight rating and raised its price target to US$149.00 from US$95.00.
Coinbase Global (COIN) — BTIG Research reiterated its Buy rating and a price target of US$240.00.
Coinbase Global (COIN) — Goldman Sachs reiterated its Buy rating and a price target of US$244.00.
ConocoPhillips (COP) — Truist Securities maintained its Hold rating and raised its price target to US$136.00 from US$130.00.
Consolidated Edison (ED) — Mizuho set its price target at US$108.00.
Constellation Brands (STZ) — Citigroup listed a Negative outlook.
Constellation Brands (STZ) — Goldman Sachs reiterated its Buy rating and a price target of US$155.00.
Cooper (COO) — Barclays initiated coverage with an Equal Weight rating and a price target of US$60.00.
Core & Main (CNM) — RBC Capital Markets maintained its Outperform rating and lowered its price target to US$57.00 from US$60.00.
Corebridge Financial (CRBG) — Barclays maintained its Overweight rating and raised its price target to US$39.00 from US$33.00.
Corebridge Financial (CRBG) — Mizuho maintained its Outperform rating and raised its price target to US$40.00 from US$38.00.
CoreWeave (CRWV) — Northland Securities set its price target at US$200.00.
Corteva (CTVA) — KeyBanc Capital Markets upgraded its rating to Overweight from Sector Weight with a price target of US$17.00.
Corteva (CTVA) — RBC Capital Markets reiterated its Outperform rating and a price target of US$17.00.
CSX (CSX) — Citigroup maintained its Neutral rating and lowered its price target to US$53.00 from US$54.00. An additional same-day entry listed a Cautious outlook without a target.
Curtiss-Wright (CW) — Citigroup maintained its Neutral rating and lowered its price target to US$622.00 from US$793.00.
Dana (DAN) — UBS maintained its Buy rating and lowered its price target to US$36.00 from US$38.00.
Danaher (DHR) — Barclays maintained its Overweight rating and raised its price target to US$255.00 from US$230.00.
Delek US (DK) — Freedom Broker initiated coverage with a Hold rating and a price target of US$86.00.
Delta Air Lines (DAL) — Bernstein maintained its Outperform rating and lowered its price target to US$100.00 from US$106.00.
Delta Air Lines (DAL) — Raymond James reiterated its Outperform rating and a price target of US$100.00.
Delta Air Lines (DAL) — Susquehanna maintained its Positive rating and lowered its price target to US$100.00 from US$105.00.
Devon Energy (DVN) — Truist Securities maintained its Buy rating and lowered its price target to US$61.00 from US$65.00.
Devon Energy (DVN) — UBS maintained its Buy rating and raised its price target to US$65.00 from US$63.00.
Dexcom (DXCM) — Barclays initiated coverage with an Overweight rating and a price target of US$115.00.
DraftKings (DKNG) — Guggenheim maintained its Buy rating and lowered its price target to US$30.00 from US$33.00.
DuPont de Nemours (DD) — Citigroup maintained its Buy rating and lowered its price target to US$162.00 from US$170.00.
e.l.f. Beauty (ELF) — Baird maintained its Outperform rating and raised its price target to US$120.00 from US$105.00.
Eagle Bancorp (EGBN) — Hovde Group initiated coverage with an Outperform rating and a price target of US$37.00.
Ecopetrol (EC) — Goldman Sachs reiterated its Neutral rating and a price target of US$17.70.
Edwards Lifesciences (EW) — Barclays initiated coverage with an Overweight rating and a price target of US$110.00.
Elevance Health (ELV) — Barclays maintained its Overweight rating and raised its price target to US$469.00 from US$457.00.
Eli Lilly and Company (LLY) — Morgan Stanley maintained its Overweight rating and raised its price target to US$1,430.00 from US$1,419.00.
ENI (E) — BNP Paribas Exane downgraded its rating to Neutral from Outperform with a price target of US$56.30.
Enova International (ENVA) — Jefferies maintained its Buy rating and lowered its price target to US$275.00 from US$300.00.
Entegris (ENTG) — Stifel set its price target at US$200.00.
Equitable (EQH) — Barclays maintained its Overweight rating and raised its price target to US$61.00 from US$52.00.
Equitable (EQH) — Mizuho maintained its Outperform rating and lowered its price target to US$66.00 from US$67.00.
Everest Group (EG) — Mizuho maintained its Neutral rating and lowered its price target to US$398.00 from US$416.00.
EVgo (EVGO) — UBS maintained its Buy rating and lowered its price target to US$2.00 from US$3.00.
Expedia Group (EXPE) — Wells Fargo maintained its Equal Weight rating and lowered its price target to US$275.00 from US$307.00.
F&G Annuities & Life (FG) — Barclays maintained its Equal Weight rating and lowered its price target to US$24.00 from US$27.00.
Federal Realty Investment Trust (FRT) — Piper Sandler reiterated its Overweight rating.
FedEx (FDX) — Citigroup maintained its Buy rating and raised its price target to US$373.00 from US$359.00. An additional same-day entry listed a Cautious outlook without a target.
FedEx (FDX) — Truist Securities maintained its Buy rating and lowered its price target to US$350.00 from US$365.00.
FedEx Freight (FDXF) — BMO Capital Markets set its price target at US$130.00.
FedEx Freight (FDXF) — Truist Securities maintained its Hold rating and lowered its price target to US$115.00 from US$155.00.
Ferguson (FERG) — RBC Capital Markets maintained its Outperform rating and lowered its price target to US$286.00 from US$290.00.
Figure Technology Solutions (FIGR) — Goldman Sachs set its price target at US$41.00.
Figure Technology Solutions (FIGR) — Needham reiterated its Buy rating.
Flowers Foods (FLO) — BNP Paribas Exane maintained its Underperform rating and lowered its price target to US$5.00 from US$6.50.
Flutter Entertainment (FLUT) — Citigroup upgraded its rating to Buy from Neutral and lowered its price target to US$91.00 from US$93.00.
Ford Motor (F) — UBS maintained its Buy rating and lowered its price target to US$15.00 from US$17.00.
Fortune Brands Innovations (FBIN) — RBC Capital Markets maintained its Outperform rating and lowered its price target to US$49.00 from US$57.00.
Fossil Group (FOSL) — Lake Street Capital initiated coverage with a Buy rating and a price target of US$10.00.
Franklin Resources (BEN) — UBS resumed coverage with a Buy rating and raised its price target to US$40.00 from US$23.00.
Freeport-McMoRan (FCX) — JPMorgan maintained its Overweight rating and raised its price target to US$92.00 from US$77.00.
Freeport-McMoRan (FCX) — Morgan Stanley maintained its Equal Weight rating and raised its price target to US$75.00 from US$70.00.
Frontier Group (ULCC) — Susquehanna maintained its Neutral rating and lowered its price target to US$6.00 from US$7.00.
GE HealthCare (GEHC) — Barclays initiated coverage with an Overweight rating and a price target of US$85.00.
General Dynamics (GD) — Citigroup maintained its Neutral rating and lowered its price target to US$374.00 from US$404.00.
General Motors (GM) — Truist Securities set its price target at US$105.00.
General Motors (GM) — UBS maintained its Buy rating and lowered its price target to US$112.00 from US$114.00.
Genmab A/S (GMAB) — H.C. Wainwright maintained its Buy rating and raised its price target to US$50.00 from US$40.00.
Genmab A/S (GMAB) — Truist Securities maintained its Buy rating and raised its price target to US$45.00 from US$40.00.
Gentex (GNTX) — UBS maintained its Neutral rating and lowered its price target to US$24.00 from US$25.00.
Gilead Sciences (GILD) — JPMorgan maintained its Overweight rating and raised its price target to US$170.00 from US$160.00.
Gilead Sciences (GILD) — Morgan Stanley maintained its Overweight rating and lowered its price target to US$163.00 from US$165.00.
Gilead Sciences (GILD) — Truist Securities maintained its Buy rating and raised its price target to US$158.00 from US$150.00.
Group 1 Automotive (GPI) — KeyBanc Capital Markets set its price target at US$425.00.
Group 1 Automotive (GPI) — UBS maintained its Neutral rating and lowered its price target to US$271.00 from US$330.00.
Groupon (GRPN) — Goldman Sachs set its price target at US$16.00.
Guardant Health (GH) — Barclays maintained its Overweight rating and raised its price target to US$220.00 from US$200.00.
Gulfport Energy (GPOR) — Mizuho set its price target at US$237.00.
Halozyme Therapeutics (HALO) — H.C. Wainwright reiterated its Buy rating.
Harrow (HROW) — BTIG Research reiterated its Buy rating and a price target of US$63.00.
HCA Healthcare (HCA) — RBC Capital Markets maintained its Outperform rating and raised its price target to US$496.00 from US$435.00.
Honeywell Aerospace (HONA) — Goldman Sachs initiated coverage with a Neutral rating and a price target of US$190.00.
Hormel Foods (HRL) — BNP Paribas Exane reiterated its Neutral rating and lowered its price target to US$23.00 from US$26.00.
Houlihan Lokey (HLI) — UBS maintained its Neutral rating and raised its price target to US$154.00 from US$147.00.
Howmet Aerospace (HWM) — Bernstein reiterated its Outperform rating and a price target of US$298.00.
HubSpot (HUBS) — Cantor Fitzgerald reiterated its Neutral rating and a price target of US$200.00.
Humacyte (HUMA) — Barclays initiated coverage with an Equal Weight rating and a price target of US$0.50.
Humana (HUM) — Cantor Fitzgerald upgraded its rating to Overweight from Neutral and raised its price target to US$460.00 from US$300.00.
Humana (HUM) — Raymond James set its price target at US$460.00.
Hut 8 (HUT) — Canaccord Genuity reiterated its Buy rating and a price target of US$130.00.
Hut 8 (HUT) — Roth Capital set its price target at US$108.00.
Iamgold (IAG) — Freedom Broker initiated coverage with a Buy rating and a price target of US$23.00.
Illumina (ILMN) — Barclays maintained its Underweight rating and raised its price target to US$200.00 from US$160.00.
IMAX (IMAX) — UBS set its price target at US$65.00.
Inspire Medical Systems (INSP) — Barclays initiated coverage with an Underweight rating and a price target of US$65.00.
Installed Building Products (IBP) — RBC Capital Markets maintained its Sector Perform rating and lowered its price target to US$208.00 from US$228.00.
Insulet (PODD) — Barclays initiated coverage with an Equal Weight rating and a price target of US$150.00.
Interactive Brokers Group (IBKR) — Barclays reiterated its Overweight rating and raised its price target to US$115.00 from US$114.00.
Interactive Brokers Group (IBKR) — UBS reiterated its Neutral rating and lowered its price target to US$101.00 from US$102.00.
Intercontinental Exchange (ICE) — Barclays reiterated its Overweight rating and raised its price target to US$189.00 from US$182.00.
Intercontinental Exchange (ICE) — Keefe, Bruyette & Woods reiterated its Outperform rating.
International Flavors & Fragrances (IFF) — Argus maintained its Buy rating and raised its price target to US$95.00 from US$85.00.
International Flavors & Fragrances (IFF) — Citigroup maintained its Buy rating and lowered its price target to US$100.00 from US$101.00.
International Paper (IP) — Wells Fargo maintained its Overweight rating and lowered its price target to US$42.00 from US$46.00.
Intuitive Surgical (ISRG) — Barclays initiated coverage with an Overweight rating and a price target of US$485.00.
Invesco (IVZ) — UBS resumed coverage with a Buy rating and a price target of US$41.00.
IQVIA (IQV) — Barclays maintained its Overweight rating and raised its price target to US$300.00 from US$275.00.
IQVIA (IQV) — Mizuho maintained its Outperform rating and raised its price target to US$300.00 from US$275.00.
Ispire Technology (ISPR) — BTIG Research set its price target at US$3.30.
J.B. Hunt Transport Services (JBHT) — BMO Capital Markets set its price target at US$315.00.
J.B. Hunt Transport Services (JBHT) — Citigroup maintained its Neutral rating and lowered its price target to US$254.00 from US$309.00. An additional same-day entry listed a Cautious outlook without a target.
J.B. Hunt Transport Services (JBHT) — Truist Securities maintained its Hold rating and lowered its price target to US$235.00 from US$295.00.
Jackson Financial (JXN) — Barclays maintained its Overweight rating and raised its price target to US$150.00 from US$149.00.
Jazz Pharmaceuticals (JAZZ) — Truist Securities maintained its Buy rating and raised its price target to US$286.00 from US$281.00.
Jersey Mike’s (JMKE) — TD Cowen maintained its Buy rating and lowered its price target to US$22.00 from US$26.00.
JetBlue Airways (JBLU) — Susquehanna maintained its Neutral rating and lowered its price target to US$4.00 from US$6.00.
Johnson & Johnson (JNJ) — Guggenheim reiterated its Buy rating and a price target of US$287.00.
Johnson Controls International (JCI) — Bernstein reiterated its Outperform rating.
Kimco Realty (KIM) — Goldman Sachs set its price target at US$24.00.
Kinsale Capital Group (KNSL) — Cantor Fitzgerald maintained its Neutral rating and raised its price target to US$264.00 from US$259.00.
Knight-Swift Transportation (KNX) — Citigroup maintained its Buy rating and lowered its price target to US$81.00 from US$90.00.
Kroger (KR) — BNP Paribas Exane upgraded its rating to Outperform from Neutral with a price target of US$72.00.
Lamb Weston (LW) — Deutsche Bank reiterated its Hold rating and a price target of US$53.00.
Lamb Weston (LW) — JPMorgan maintained its Neutral rating and raised its price target to US$53.00 from US$46.00.
Lamb Weston (LW) — Wells Fargo maintained its Overweight rating and lowered its price target to US$54.00 from US$57.00.
Landstar System (LSTR) — Truist Securities maintained its Hold rating and lowered its price target to US$175.00 from US$185.00.
Lazard (LAZ) — UBS maintained its Neutral rating and lowered its price target to US$40.00 from US$44.00.
Lear (LEA) — UBS maintained its Neutral rating and lowered its price target to US$132.00 from US$141.00.
Leidos (LDOS) — Citigroup maintained its Buy rating and lowered its price target to US$141.00 from US$161.00.
Lennar (LEN) — Wells Fargo maintained its Equal Weight rating and lowered its price target to US$75.00 from US$80.00.
Lincoln National (LNC) — Barclays maintained its Overweight rating and raised its price target to US$48.00 from US$45.00.
Lincoln National (LNC) — Mizuho maintained its Outperform rating and lowered its price target to US$49.00 from US$53.00.
Lincoln National (LNC) — National Bank Financial set its price target at US$49.00.
Linde (LIN) — Citigroup maintained its Buy rating and lowered its price target to US$560.00 from US$580.00.
Lithia Motors (LAD) — UBS maintained its Neutral rating and lowered its price target to US$335.00 from US$440.00.
LivaNova (LIVN) — Barclays initiated coverage with an Overweight rating and a price target of US$105.00.
Live Oak Bancshares (LOB) — Piper Sandler maintained its Neutral rating and lowered its price target to US$38.00 from US$46.00.
LPL Financial (LPLA) — Barclays maintained its Overweight rating and raised its price target to US$409.00 from US$401.00.
LPL Financial (LPLA) — JPMorgan maintained its Overweight rating and raised its price target to US$445.00 from US$428.00.
LPL Financial (LPLA) — UBS maintained its Buy rating and lowered its price target to US$390.00 from US$391.00.
M&T Bank (MTB) — Raymond James initiated coverage with an Outperform rating and a price target of US$250.00.
MannKind (MNKD) — Truist Securities maintained its Buy rating and lowered its price target to US$5.00 from US$6.00.
Marex Group plc Ordinary Shares (MRX) — Barclays maintained its Overweight rating and raised its price target to US$92.00 from US$86.00.
Marsh & McLennan Companies (MRSH) — Mizuho maintained its Neutral rating and lowered its price target to US$190.00 from US$201.00.
Marvell Technology (MRVL) — BMO Capital Markets reiterated its Market Perform rating and a price target of US$325.00.
Marvell Technology (MRVL) — Cantor Fitzgerald maintained its Neutral rating and raised its price target to US$350.00 from US$330.00.
Marvell Technology (MRVL) — Craig-Hallum reiterated its Buy rating and a price target of US$380.00.
Marvell Technology (MRVL) — Goldman Sachs reiterated its Neutral rating and a price target of US$270.00.
Marvell Technology (MRVL) — JPMorgan maintained its Overweight rating and raised its price target to US$360.00 from US$305.00.
Marvell Technology (MRVL) — KeyBanc Capital Markets reiterated its Overweight rating.
Marvell Technology (MRVL) — Morgan Stanley maintained its Equal Weight rating and raised its price target to US$300.00 from US$268.00.
Marvell Technology (MRVL) — Needham maintained its Buy rating and raised its price target to US$400.00 from US$300.00.
Marvell Technology (MRVL) — Oppenheimer reiterated its Outperform rating and a price target of US$425.00.
Marvell Technology (MRVL) — Piper Sandler maintained its Overweight rating and raised its price target to US$400.00 from US$270.00.
Marvell Technology (MRVL) — RBC Capital Markets maintained its Outperform rating and raised its price target to US$425.00 from US$360.00.
Marvell Technology (MRVL) — Stifel maintained its Buy rating and raised its price target to US$370.00 from US$350.00.
Marvell Technology (MRVL) — Susquehanna maintained its Positive rating and raised its price target to US$340.00 from US$265.00.
Marvell Technology (MRVL) — TD Cowen upgraded its rating to Buy from Hold and raised its price target to US$350.00 from US$245.00.
Marvell Technology (MRVL) — UBS maintained its Buy rating and raised its price target to US$350.00 from US$335.00.
Marvell Technology (MRVL) — Wells Fargo maintained its Overweight rating and raised its price target to US$365.00 from US$310.00.
Marvell Technology (MRVL) — Wolfe Research maintained its Outperform rating and raised its price target to US$375.00 from US$280.00.
Masco (MAS) — RBC Capital Markets maintained its Sector Perform rating and lowered its price target to US$69.00 from US$72.00.
MasTec (MTZ) — Mizuho set its price target at US$352.00.
McKesson (MCK) — Leerink Partners maintained its Outperform rating and raised its price target to US$1,070.00 from US$1,030.00.
Medpace (MEDP) — Barclays maintained its Equal Weight rating and raised its price target to US$625.00 from US$600.00.
Medpace (MEDP) — Mizuho maintained its Outperform rating and raised its price target to US$700.00 from US$665.00.
Medtronic (MDT) — Barclays initiated coverage with an Equal Weight rating and a price target of US$95.00.
Merck & Co., Inc. (MRK) — Morgan Stanley maintained its Overweight rating and lowered its price target to US$177.00 from US$179.00.
MetLife (MET) — Barclays maintained its Overweight rating and raised its price target to US$111.00 from US$97.00.
MetLife (MET) — Mizuho maintained its Outperform rating and lowered its price target to US$109.00 from US$112.00.
Mettler-Toledo International (MTD) — Barclays maintained its Overweight rating and raised its price target to US$1,700.00 from US$1,575.00.
Micron Technology (MU) — DA Davidson maintained its Buy rating and raised its price target to US$3,000.00 from US$2,100.00.
MiniMed Group (MMED) — Barclays initiated coverage with an Equal Weight rating and a price target of US$22.00.
Mobileye Global (MBLY) — UBS maintained its Neutral rating and lowered its price target to US$7.50 from US$9.00.
Moderna (MRNA) — Morgan Stanley maintained its Equal Weight rating and raised its price target to US$95.00 from US$89.00.
Moelis & Company (MC) — UBS upgraded its rating to Neutral from Sell and lowered its price target to US$59.00 from US$60.00.
Mohawk Industries (MHK) — RBC Capital Markets downgraded its rating to Underperform from Sector Perform and lowered its price target to US$112.00 from US$130.00.
Moody’s (MCO) — Morgan Stanley maintained its Equal Weight rating and lowered its price target to US$470.00 from US$512.00.
MP Materials (MP) — Morgan Stanley maintained its Overweight rating and lowered its price target to US$66.00 from US$73.00.
Nasdaq (NDAQ) — Barclays reiterated its Overweight rating and lowered its price target to US$109.00 from US$111.00.
Natera (NTRA) — Barclays maintained its Overweight rating and raised its price target to US$475.00 from US$340.00.
Nayax (NYAX) — Jefferies reiterated its Buy rating and a price target of US$68.30.
NeoGenomics (NEO) — Piper Sandler reiterated its Overweight rating.
Neostellar Capital (NSLR) — BTIG Research maintained its Buy rating and lowered its price target to US$14.00 from US$15.00.
Neptune Insurance (NP) — Mizuho maintained its Neutral rating and lowered its price target to US$31.00 from US$32.00.
NetApp (NTAP) — Cantor Fitzgerald upgraded its rating to Overweight.
NetApp (NTAP) — Evercore ISI upgraded its rating to Outperform from In-Line with a price target of US$300.00.
NetApp (NTAP) — Loop Capital set its price target at US$300.00.
Netflix (NFLX) — Barclays maintained its Equal Weight rating and lowered its price target to US$70.00 from US$80.00.
New Era Energy & Digital (NUAI) — Roth Capital initiated coverage with a Buy rating and a price target of US$10.00.
Nexa Resources (NEXA) — Morgan Stanley upgraded its rating to Overweight from Equal Weight with a price target of US$14.20.
Nextpower (NXT) — Citigroup maintained its Buy rating and lowered its price target to US$121.00 from US$132.00.
nLight (LASR) — Northcoast Research upgraded its rating to Buy from Neutral with a price target of US$75.00.
Nomad Foods (NOMD) — Deutsche Bank reiterated its Hold rating and a price target of US$12.00.
Norfolk Southern (NSC) — Citigroup maintained its Neutral rating and lowered its price target to US$347.00 from US$376.00. An additional same-day entry listed a Cautious outlook without a target.
OKYO Pharma (OKYO) — H.C. Wainwright reiterated its Buy rating.
Old Dominion Freight Line (ODFL) — BMO Capital Markets set its price target at US$235.00.
Old Dominion Freight Line (ODFL) — Truist Securities maintained its Buy rating and lowered its price target to US$230.00 from US$250.00.
Old Dominion Freight Line (ODFL) — Wolfe Research upgraded its rating to Peer Perform from Underperform.
OmniAb (OABI) — Leerink Partners maintained its Outperform rating and raised its price target to US$12.00 from US$10.00.
ONE Gas (OGS) — Jefferies downgraded its rating to Hold from Buy with a price target of US$80.00.
Oportun Financial (OPRT) — Jefferies maintained its Hold rating and raised its price target to US$9.00 from US$6.00.
Option Care Health (OPCH) — Barrington Research changed its rating to Market Perform from Outperform.
Option Care Health (OPCH) — Citizens JMP Securities changed its rating to Market Perform from Market Outperform.
Option Care Health (OPCH) — JPMorgan changed its rating to Neutral from Overweight with a price target of US$33.00.
Option Care Health (OPCH) — Truist Securities set its price target at US$32.05.
Oruka Therapeutics (ORKA) — Piper Sandler reiterated its Overweight rating.
Owens Corning (OC) — RBC Capital Markets downgraded its rating to Sector Perform from Outperform and lowered its price target to US$127.00 from US$172.00.
Owens Corning (OC) — Vertical Research downgraded its rating to Sell from Hold with a price target of US$106.00.
Pacira BioSciences (PCRX) — Truist Securities maintained its Buy rating and raised its price target to US$31.00 from US$30.00.
Packaging Corporation of America (PKG) — Wells Fargo maintained its Equal Weight rating and lowered its price target to US$245.00 from US$246.00.
Pembina Pipeline (PBA) — Barclays reiterated its Overweight rating.
Penguin Solutions (PENG) — Barclays maintained its Underweight rating and raised its price target to US$60.00 from US$40.00.
Penguin Solutions (PENG) — Goldman Sachs reiterated its Buy rating and a price target of US$85.00.
Penguin Solutions (PENG) — Needham maintained its Buy rating and raised its price target to US$85.00 from US$80.00.
Penguin Solutions (PENG) — Rosenblatt Securities maintained its Buy rating and raised its price target to US$100.00 from US$80.00.
Penguin Solutions (PENG) — Stifel maintained its Buy rating and raised its price target to US$85.00 from US$75.00.
Phillips Edison & Company, Inc. (PECO) — Goldman Sachs set its price target at US$44.00.
PHINIA (PHIN) — UBS maintained its Neutral rating and lowered its price target to US$68.00 from US$80.00.
PJT Partners (PJT) — Keefe, Bruyette & Woods downgraded its rating to Market Perform from Outperform and lowered its price target to US$159.00 from US$195.00.
PJT Partners (PJT) — UBS maintained its Neutral rating and lowered its price target to US$165.00 from US$176.00.
Polaris (PII) — Baird maintained its Neutral rating and lowered its price target to US$65.00 from US$72.00.
Principal Financial Group (PFG) — Barclays maintained its Underweight rating and lowered its price target to US$86.00 from US$92.00.
PROCEPT BioRobotics (PRCT) — Barclays initiated coverage with an Overweight rating and a price target of US$30.00.
PROG (PRG) — Jefferies maintained its Buy rating and lowered its price target to US$50.00 from US$60.00.
Progressive (PGR) — Barclays maintained its Overweight rating and raised its price target to US$247.00 from US$246.00.
Progressive (PGR) — HSBC reiterated its Hold rating and a price target of US$216.00.
Prudential Financial (PRU) — Barclays maintained its Underweight rating and raised its price target to US$96.00 from US$92.00.
Prudential Financial (PRU) — Mizuho maintained its Neutral rating and lowered its price target to US$109.00 from US$113.00.
PTC Therapeutics (PTCT) — RBC Capital Markets reiterated its Sector Perform rating.
Quanta Services (PWR) — Mizuho set its price target at US$684.00.
Quest Diagnostics (DGX) — Barclays maintained its Overweight rating and raised its price target to US$260.00 from US$250.00.
QXO (QXO) — RBC Capital Markets maintained its Outperform rating and lowered its price target to US$18.00 from US$27.00.
Raymond James Financial (RJF) — Barclays reiterated its Overweight rating and raised its price target to US$197.00 from US$196.00.
Raymond James Financial (RJF) — UBS maintained its Neutral rating and lowered its price target to US$179.00 from US$184.00.
Regeneron Pharmaceuticals (REGN) — Morgan Stanley maintained its Equal Weight rating and raised its price target to US$779.00 from US$758.00.
Regeneron Pharmaceuticals (REGN) — Truist Securities maintained its Buy rating and raised its price target to US$780.00 from US$772.00.
Reinsurance Group of America (RGA) — Barclays maintained its Overweight rating and lowered its price target to US$286.00 from US$290.00.
Repligen (RGEN) — Barclays maintained its Overweight rating and raised its price target to US$225.00 from US$175.00.
Restaurant Brands International (QSR) — TD Cowen maintained its Hold rating and lowered its price target to US$78.00 from US$80.00.
Revolution Medicines (RVMD) — Truist Securities maintained its Buy rating and raised its price target to US$240.00 from US$239.00.
Revvity (RVTY) — Barclays maintained its Equal Weight rating and raised its price target to US$160.00 from US$115.00.
Rezolve AI (RZLV) — Cantor Fitzgerald reiterated its Overweight rating.
Robinhood Markets (HOOD) — Barclays maintained its Overweight rating and raised its price target to US$132.00 from US$105.00.
Rocket Pharmaceuticals (RCKT) — Cantor Fitzgerald reiterated its Overweight rating.
Rocket Pharmaceuticals (RCKT) — Chardan Capital reiterated its Buy rating and a price target of US$11.00.
Rocket Pharmaceuticals (RCKT) — Jefferies reiterated its Hold rating and a price target of US$2.95.
Rocket Pharmaceuticals (RCKT) — Leerink Partners maintained its Market Perform rating and lowered its price target to US$4.00 from US$7.00.
Rocket Pharmaceuticals (RCKT) — Wedbush reiterated its Outperform rating.
Royal Caribbean Cruises (RCL) — Barclays maintained its Overweight rating and lowered its price target to US$337.00 from US$340.00.
Royalty Pharma (RPRX) — Morgan Stanley maintained its Overweight rating and raised its price target to US$67.00 from US$65.00.
RPM International (RPM) — Citigroup maintained its Buy rating and lowered its price target to US$116.00 from US$128.00.
RPM International (RPM) — RBC Capital Markets maintained its Outperform rating and lowered its price target to US$120.00 from US$128.00.
RPM International (RPM) — UBS maintained its Buy rating and lowered its price target to US$128.00 from US$142.00.
RTX (RTX) — Citigroup reiterated its Buy rating.
RXO (RXO) — Truist Securities maintained its Buy rating and raised its price target to US$30.00 from US$28.00.
Ryan Specialty (RYAN) — Mizuho maintained its Neutral rating and lowered its price target to US$40.00 from US$43.00.
S&P Global (SPGI) — Morgan Stanley maintained its Overweight rating and lowered its price target to US$477.00 from US$525.00.
Saia (SAIA) — Citigroup maintained its Buy rating and raised its price target to US$429.00 from US$417.00. An additional same-day entry listed a Cautious outlook without a target.
SailPoint (SAIL) — Jefferies reiterated its Buy rating.
SailPoint (SAIL) — Oppenheimer initiated coverage with an Outperform rating and a price target of US$30.00.
Savara (SVRA) — Citigroup reiterated its Market Outperform rating.
Savara (SVRA) — JPMorgan initiated coverage with an Overweight rating and a price target of US$12.00.
Savara (SVRA) — RBC Capital Markets set its price target at US$10.00.
Schneider National (SNDR) — Citigroup maintained its Neutral rating and lowered its price target to US$33.00 from US$38.00. An additional same-day entry listed a Cautious outlook without a target.
Sensata Technologies (ST) — UBS maintained its Buy rating and lowered its price target to US$54.00 from US$57.00.
Senseonics Holdings, Inc. Common Stock (SENS) — Barclays initiated coverage with an Equal Weight rating and a price target of US$10.00.
ServiceNow (NOW) — Argus maintained its Buy rating and raised its price target to US$170.00 from US$134.00.
Simulations Plus (SLP) — BTIG Research reiterated its Neutral rating.
SiteOne Landscape Supply (SITE) — RBC Capital Markets maintained its Outperform rating and lowered its price target to US$124.00 from US$135.00.
SiteOne Landscape Supply (SITE) — William Blair reiterated its Market Perform rating.
Skydance (SKYD) — Barclays maintained its Underweight rating and lowered its price target to US$7.00 from US$8.00.
SM Energy (SM) — Mizuho set its price target at US$39.00.
SM Energy (SM) — Truist Securities maintained its Buy rating and raised its price target to US$48.00 from US$43.00.
SolarEdge Technologies (SEDG) — Barclays maintained its Equal Weight rating and lowered its price target to US$36.00 from US$37.00.
Solstice Advance Materials (SOLS) — Seaport Research Partners initiated coverage with a Buy rating and a price target of US$80.00.
Sonic Automotive (SAH) — UBS maintained its Buy rating and lowered its price target to US$74.00 from US$107.00.
Southern Copper (SCCO) — Morgan Stanley reiterated its Underweight rating and a price target of US$170.00.
Southwest Airlines (LUV) — Susquehanna maintained its Neutral rating and lowered its price target to US$45.00 from US$50.00.
SpaceX (SPCX) — Susquehanna maintained its Neutral rating and raised its price target to US$173.00 from US$144.00.
Stevanato Group (STVN) — Deutsche Bank initiated coverage with a Hold rating.
Stifel Financial (SF) — UBS reiterated its Buy rating and lowered its price target to US$84.00 from US$90.00.
Stryker (SYK) — Barclays initiated coverage with an Overweight rating and a price target of US$375.00.
Stryker (SYK) — Bernstein reiterated its Market Perform rating.
Sun Life Financial (SLF) — Barclays reiterated its Underweight rating.
Sunshine Silver Mining & Refining (SSMR) — Morgan Stanley maintained its Overweight rating and lowered its price target to US$20.00 from US$23.00.
T. Rowe Price (TROW) — UBS resumed coverage with a Neutral rating and a price target of US$107.00.
Tandem Diabetes Care (TNDM) — Barclays initiated coverage with an Equal Weight rating and a price target of US$18.00.
Tanger (SKT) — Goldman Sachs set its price target at US$40.00.
TE Connectivity (TEL) — UBS maintained its Buy rating and raised its price target to US$253.00 from US$241.00.
Textron (TXT) — Citigroup reiterated its Neutral rating and lowered its price target to US$86.00 from US$99.00.
TFI International (TFII) — BMO Capital Markets reiterated its Market Perform rating.
TFI International (TFII) — Citigroup maintained its Buy rating and a price target of US$100.00.
The Hartford Insurance Group (HIG) — Cantor Fitzgerald maintained its Overweight rating and raised its price target to US$145.00 from US$144.00.
The Hartford Insurance Group (HIG) — Mizuho maintained its Neutral rating and lowered its price target to US$144.00 from US$154.00.
TransMedics Group (TMDX) — Barclays initiated coverage with an Overweight rating and a price target of US$120.00.
Twist Bioscience (TWST) — Barclays maintained its Overweight rating and raised its price target to US$215.00 from US$112.00.
Uber Technologies (UBER) — Citigroup reiterated its Market Outperform rating.
Uber Technologies (UBER) — Citizens JMP Securities reiterated its Market Outperform rating and a price target of US$100.00.
Union Pacific (UNP) — Citigroup maintained its Buy rating and lowered its price target to US$338.00 from US$349.00. An additional same-day entry listed a Cautious outlook without a target.
United Airlines (UAL) — Susquehanna maintained its Positive rating and lowered its price target to US$150.00 from US$165.00.
United Parcel Service (UPS) — Citigroup maintained its Buy rating and lowered its price target to US$122.00 from US$132.00.
United Parcel Service (UPS) — Truist Securities maintained its Buy rating and lowered its price target to US$115.00 from US$130.00.
United Therapeutics (UTHR) — Morgan Stanley maintained its Equal Weight rating and raised its price target to US$566.00 from US$515.00.
Unum Group (UNM) — Barclays maintained its Overweight rating and lowered its price target to US$109.00 from US$110.00.
UWM (UWMC) — Keefe, Bruyette & Woods downgraded its rating to Market Perform from Outperform with a price target of US$1.50.
Vale (VALE) — Morgan Stanley set its price target at US$15.50.
Venture Global (VG) — RBC Capital Markets reiterated its Outperform rating.
Via Transportation (VIA) — Deutsche Bank reiterated its Buy rating and a price target of US$35.00.
Viking Therapeutics (VKTX) — Truist Securities maintained its Buy rating and lowered its price target to US$85.00 from US$87.00.
Vir Biotechnology (VIR) — H.C. Wainwright maintained its Buy rating and raised its price target to US$22.00 from US$20.00.
Visteon (VC) — UBS set its price target at US$107.00.
Voya Financial (VOYA) — Barclays maintained its Overweight rating and raised its price target to US$109.00 from US$105.00.
VSE (VSEC) — Citigroup reiterated its Buy rating.
Vylor (VYLR) — KeyBanc Capital Markets initiated coverage with a Sector Weight rating and a price target of US$78.00.
W.R. Berkley (WRB) — Cantor Fitzgerald maintained its Neutral rating and raised its price target to US$74.00 from US$73.00.
W.R. Berkley (WRB) — Mizuho maintained its Neutral rating and lowered its price target to US$70.00 from US$72.00.
Waters (WAT) — Barclays maintained its Overweight rating and raised its price target to US$500.00 from US$460.00.
Wealthfront (WLTH) — Goldman Sachs reiterated its Neutral rating and a price target of US$11.00.
Wealthfront (WLTH) — Needham reiterated its Buy rating and a price target of US$13.00.
Werner Enterprises (WERN) — Citigroup maintained its Neutral rating and lowered its price target to US$37.00 from US$43.00.
West Pharmaceutical Services (WST) — Barclays maintained its Overweight rating and raised its price target to US$440.00 from US$400.00.
Whirlpool (WHR) — RBC Capital Markets maintained its Underperform rating and lowered its price target to US$22.00 from US$32.00.
Willis Towers Watson Public (WTW) — Barclays maintained its Equal Weight rating and raised its price target to US$332.00 from US$303.00.
Willis Towers Watson Public (WTW) — Mizuho maintained its Outperform rating and lowered its price target to US$349.00 from US$380.00.
XPO (XPO) — BMO Capital Markets reiterated its Outperform rating.
XPO (XPO) — Citigroup upgraded its rating to Buy from Neutral and raised its price target to US$224.00 from US$220.00.
XPO (XPO) — Truist Securities maintained its Buy rating and lowered its price target to US$220.00 from US$240.00.
Yum! Brands (YUM) — TD Cowen maintained its Buy rating and lowered its price target to US$177.00 from US$180.00.
Zimmer Biomet (ZBH) — Barclays initiated coverage with an Equal Weight rating and a price target of US$100.00.
Zscaler (ZS) — Baird maintained its Outperform rating and raised its price target to US$285.00 from US$230.00.
Zscaler (ZS) — Barclays maintained its Overweight rating and raised its price target to US$225.00 from US$220.00.
Zscaler (ZS) — BNP Paribas Exane reiterated its Outperform rating and raised its price target to US$250.00 from US$230.00.
Zscaler (ZS) — BTIG Research reiterated its Neutral rating.
Zscaler (ZS) — Canaccord Genuity maintained its Buy rating and raised its price target to US$250.00 from US$210.00.
Zscaler (ZS) — Cantor Fitzgerald maintained its Overweight rating and raised its price target to US$275.00 from US$225.00.
Zscaler (ZS) — Citigroup maintained its Buy rating and raised its price target to US$245.00 from US$205.00.
Zscaler (ZS) — Guggenheim maintained its Buy rating and raised its price target to US$254.00 from US$214.00.
Zscaler (ZS) — Jefferies maintained its Buy rating and raised its price target to US$250.00 from US$220.00.
Zscaler (ZS) — JPMorgan maintained its Overweight rating and raised its price target to US$245.00 from US$215.00.
Zscaler (ZS) — Mizuho set its price target at US$235.00.
Zscaler (ZS) — Morgan Stanley maintained its Equal Weight rating and raised its price target to US$185.00 from US$165.00.
Zscaler (ZS) — Needham maintained its Buy rating and raised its price target to US$255.00 from US$215.00.
Zscaler (ZS) — RBC Capital Markets reiterated its Outperform rating and a price target of US$236.00.
Zscaler (ZS) — Rosenblatt Securities set its price target at US$250.00.
Zscaler (ZS) — Scotiabank maintained its Sector Outperform rating and raised its price target to US$255.00 from US$240.00.
Zscaler (ZS) — Stephens maintained its Overweight rating and raised its price target to US$265.00 from US$225.00.
Zscaler (ZS) — Stifel maintained its Buy rating and raised its price target to US$235.00 from US$200.00.
Zscaler (ZS) — TD Cowen maintained its Buy rating and raised its price target to US$230.00 from US$200.00.
Zscaler (ZS) — Truist Securities reiterated its Buy rating and raised its price target to US$250.00 from US$200.00.
Zscaler (ZS) — Wedbush maintained its Outperform rating and raised its price target to US$240.00 from US$215.00.
Zscaler (ZS) — Wells Fargo maintained its Overweight rating and raised its price target to US$260.00 from US$215.00.
Zymeworks (ZYME) — Truist Securities maintained its Buy rating and raised its price target to US$34.00 from US$32.00.
The post U.S. Analyst Updates: October 7th, 2026 appeared first on Stock Target Advisor.
